Artivion (AORT) said Monday it has received a humanitarian device exemption from the US Food and Drug Administration, allowing the commercial distribution of its AMDS hybrid prosthesis device to treat acute DeBakey Type 1 aortic dissections.
Under HDE, the AMDS hybrid prosthesis will be available as a treatment for acute DeBakey Type 1 dissections in the presence of malperfusion, Artivion said. If its premarket approval application for the device is approved, the device may be used in all DeBakey Type 1 dissections, including those without malperfusion, the company added.
Artivion said the HDE helps position AMDS hybrid prosthesis for a broader commercial launch, letting the company obtain approvals from institutional review boards and hospital value analysis committees and starting the process of training surgeons to implant the device.
Artivion shares were down more than 3% in recent trading.
Price: 28.73, Change: -0.93, Percent Change: -3.15
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。